CO2022015891A2 - Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres - Google Patents

Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres

Info

Publication number
CO2022015891A2
CO2022015891A2 CONC2022/0015891A CO2022015891A CO2022015891A2 CO 2022015891 A2 CO2022015891 A2 CO 2022015891A2 CO 2022015891 A CO2022015891 A CO 2022015891A CO 2022015891 A2 CO2022015891 A2 CO 2022015891A2
Authority
CO
Colombia
Prior art keywords
mirdametinib
lifirafenib
cancers
treatment
pharmaceutically acceptable
Prior art date
Application number
CONC2022/0015891A
Other languages
English (en)
Inventor
Todd Webster Shearer
Badreddin Edris
Lusong Luo
Zhiyu Tang
Original Assignee
Springworks Therapeutics Inc
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc, Beigene Ltd filed Critical Springworks Therapeutics Inc
Publication of CO2022015891A2 publication Critical patent/CO2022015891A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a métodos para tratar cánceres que comprenden la administración conjunta de mirdametinib o una forma de sal farmacéuticamente aceptable de este y lifirafenib o una forma de sal farmacéuticamente aceptable de este a un paciente que lo necesita. También se describen composiciones farmacéuticas de mirdametinib o una forma de sal farmacéuticamente aceptable de este y lifirafenib o una forma de sal farmacéuticamente aceptable de este para uso en tal tratamiento del cáncer, así como usos de estos compuestos para la elaboración de medicamentos para el tratamiento de cánceres.
CONC2022/0015891A 2020-04-03 2022-11-03 Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres CO2022015891A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063005153P 2020-04-03 2020-04-03
PCT/US2021/025551 WO2021202981A1 (en) 2020-04-03 2021-04-02 Co-administration of mirdametinib and lifirafenib for use in treating cancers

Publications (1)

Publication Number Publication Date
CO2022015891A2 true CO2022015891A2 (es) 2023-05-08

Family

ID=75674969

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015891A CO2022015891A2 (es) 2020-04-03 2022-11-03 Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres

Country Status (16)

Country Link
US (1) US20230128315A1 (es)
EP (1) EP4125842B1 (es)
JP (1) JP2023521036A (es)
KR (1) KR20230048476A (es)
CN (1) CN116194095A (es)
AU (1) AU2021246141A1 (es)
BR (1) BR112022019914A2 (es)
CA (1) CA3174223A1 (es)
CL (1) CL2022002682A1 (es)
CO (1) CO2022015891A2 (es)
DK (1) DK4125842T3 (es)
IL (1) IL296878A (es)
MX (1) MX2022012351A (es)
PE (1) PE20231211A1 (es)
TW (1) TW202207910A (es)
WO (1) WO2021202981A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806321B2 (en) * 2022-03-17 2023-11-07 Springworks Therapeutics, Inc. Non-linear dosing of mirdametinib
US20230293464A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of pancreatic ductal adenocarcinoma with mirdametinib
WO2023209611A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
WO2024081948A1 (en) * 2022-10-14 2024-04-18 Springworks Therapeutics, Inc. Combination for use in treating cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6147246B2 (ja) * 2011-04-01 2017-06-14 ジェネンテック， インコーポレイテッド Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
WO2019113345A1 (en) * 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases
EP3560516A1 (en) * 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof

Also Published As

Publication number Publication date
EP4125842A1 (en) 2023-02-08
JP2023521036A (ja) 2023-05-23
TW202207910A (zh) 2022-03-01
BR112022019914A2 (pt) 2022-12-13
AU2021246141A1 (en) 2022-12-01
IL296878A (en) 2022-12-01
CA3174223A1 (en) 2021-10-07
WO2021202981A1 (en) 2021-10-07
EP4125842B1 (en) 2024-06-05
CN116194095A (zh) 2023-05-30
DK4125842T3 (da) 2024-07-22
CL2022002682A1 (es) 2023-06-16
US20230128315A1 (en) 2023-04-27
KR20230048476A (ko) 2023-04-11
MX2022012351A (es) 2023-03-13
PE20231211A1 (es) 2023-08-17

Similar Documents

Publication Publication Date Title
CO2022015891A2 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY31800A (es) Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR078588A1 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CO2020013968A2 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer
ECSP23096498A (es) Restos de administración terapéutica novedosos y usos de estos
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
MX2018003685A (es) Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento.
CL2023002549A1 (es) Ciertos compuestos de pladienolida y métodos de uso (divisional).
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
RU2014137190A (ru) Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
AR085132A1 (es) Composiciones farmaceuticas para el tratamiento de glioma maligno
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
AR108792A1 (es) Composiciones que comprenden timolol